Showing 1-10 of about 68 articles.
Raptor Pharmaceutical Corp.
Raptor Pharmaceutical Corp. to Present at Upcoming Investor Conferences
NOVATO, Calif., Feb. 5, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP), today announced that the company's management will present at two upcoming investor conferences in February. Julie Anne Smith, executive vice president, strategy and chief operating officer of Raptor, will present an overview of the company at the 15th Annual BIO CEO & Investor Conference on February 12, 2013, at 11:00 a.m. ET/8:00 a.m. PT. Christopher M. Starr, Ph.D., Raptor's CEO and Julie Anne Smith will present at the Leerink Swann Global Healthcare Conference on February 12, 2013, at 8:30 a.m. ET/5:30 a.m. PT. Both conferences will be held at the Waldorf-Astoria in New York.
Raptor Pharmaceutical Corp.
Raptor Pharmaceutical Corp. Provides Update on PROCYSBI(TM) NDA Review
NOVATO, Calif., Dec. 21, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that the U.S. Food and Drug Administration ("FDA") will require additional time to complete its review of the New Drug Application ("NDA") for RP103 (PROCYSBI™), for the potential treatment of nephropathic cystinosis. In a notice received today from the FDA, the initial Prescription Drug User Fee Act ("PDUFA") goal date has been extended from January 30, 2013 to April 30, 2013. The three month extension is a standard extension period.
Showing 1-10 of about 68 articles.